AstraZeneca plans to begin early and mid-term clinical trial tests of its Covid-19 vaccine in China this year. A senior official of the company said this on Friday.
The company plans to release the vaccine globally soon. A report by the news agency Reuters has given this information.
The AstraZeneca vaccine is already being tested in several countries. AstraZeneca developing the vaccine in collaboration with Oxford University in the United Kingdom. The company is expecting the results of the last phase of the vaccine test this year.
AstraZeneca CEO Pascal Sariot said this week that they would seek permission for emergency use in various countries as soon as they know the results of the ticker after the test.
Shenzhen Kangati has entered into an agreement with Biological Products to test for the AstraZeneca vaccine in China.
According to the agreement, Chinese vaccine maker Shenzhen Kangati will produce 100 million doses of the vaccine this year.
AstraZeneca CEO and authorities say the first and second rounds of testing for the vaccine in China as well as the results of the third stage at the global level could lead to the approval of the vaccine in China by the middle of next year.